Bladder Cancer Treatment Landscape Shifts: ImmunityBio’s Long-Term Data Challenges Surgical Intervention Rates

ImmunityBio's latest clinical findings reveal a significant development in the ongoing battle against non-muscle-invasive bladder cancer, with three-year follow-up data suggesting that combining Anktiva with standard immunotherapy could fundamentally alter…

Continue Reading Bladder Cancer Treatment Landscape Shifts: ImmunityBio’s Long-Term Data Challenges Surgical Intervention Rates

FibroBiologics Advances Innovative Cell Therapy: FDA Review of CYPS317 for Psoriasis Treatment Marks Major Clinical Milestone

FibroBiologics Inc, a clinical-stage biotechnology company, has announced a significant breakthrough in regenerative medicine by submitting a Phase 1/2 Investigational New Drug (IND) application to the US Food and Drug…

Continue Reading FibroBiologics Advances Innovative Cell Therapy: FDA Review of CYPS317 for Psoriasis Treatment Marks Major Clinical Milestone

It Was All a Dream

Editor's Note: Patient Worthy is honored to share Michelle Patidar's patient story, provided to us by our friends at Elephants & Tea. To see the article in its original format,…

Continue Reading It Was All a Dream

From Cancer Treatment to Childhood Health: How Foresee’s Injectable Drug Addresses a Rare Pediatric Challenge

When pharmaceutical companies develop medications for serious diseases like prostate cancer, few anticipate how those treatments might transform care for entirely different patient populations. Yet, according to FiercePharma.com, Foresee Pharmaceuticals…

Continue Reading From Cancer Treatment to Childhood Health: How Foresee’s Injectable Drug Addresses a Rare Pediatric Challenge

Pemvidutide Shows Sustained Weight Loss and Liver Improvement in Extended MASH Trial Data

Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating continued weight loss and…

Continue Reading Pemvidutide Shows Sustained Weight Loss and Liver Improvement in Extended MASH Trial Data

CRISPR Therapeutics Shares Promising Updates on Zugo-cel in Autoimmune and Oncology Trials

CRISPR Therapeutics has announced encouraging early results for zugocaptagene geleucel (zugo-cel), its investigational allogeneic CAR T therapy targeting CD19, in both autoimmune diseases and hematologic malignancies. Autoimmune Disease Progress In…

Continue Reading CRISPR Therapeutics Shares Promising Updates on Zugo-cel in Autoimmune and Oncology Trials

Coya Therapeutics Advances Novel Immunotherapy into Clinical Development for Frontotemporal Dementia

Coya Therapeutics has achieved an important regulatory milestone with U.S. FDA acceptance of an Investigational New Drug (IND) application for COYA 302, marking the advancement of a promising new treatment…

Continue Reading Coya Therapeutics Advances Novel Immunotherapy into Clinical Development for Frontotemporal Dementia

Deucrictibant Provides Rapid Relief for Hereditary Angioedema Attack Symptoms

A new oral medication has demonstrated remarkable effectiveness in treating hereditary angioedema (HAE) attacks, offering patients significantly faster symptom relief compared to existing options. According to Healio.com, the RAPIDe-3 study…

Continue Reading Deucrictibant Provides Rapid Relief for Hereditary Angioedema Attack Symptoms

Incyte Reports Positive Phase III Results for Tafasitamab in First-Line DLBCL Treatment

Incyte has announced encouraging top-line findings from its pivotal Phase III frontMIND trial, evaluating tafasitamab (marketed as Monjuvi/Minjuvi) in combination with lenalidomide and the standard R-CHOP regimen for newly diagnosed…

Continue Reading Incyte Reports Positive Phase III Results for Tafasitamab in First-Line DLBCL Treatment

FDA Approve Drug That Targets Root Cause of Life-Threatening Kidney Disease Affecting Children and Young Adults 

Iowa University researchers at its Children’s Hospital led the effort that found a new target.  According to the Iowa Carver College of Medicine, to date, efforts by researchers focused on…

Continue Reading FDA Approve Drug That Targets Root Cause of Life-Threatening Kidney Disease Affecting Children and Young Adults 

Tonsillectomy Plus Immunosuppression Improves Outcomes in High-Risk IgA Nephropathy Among Caucasians

Editor's Note: The following study results were first published in Nephrology Dialysis Transplantation (December 16, 2025) and later shared in the Oxford Academic. The original study authors are Zinaida S.…

Continue Reading Tonsillectomy Plus Immunosuppression Improves Outcomes in High-Risk IgA Nephropathy Among Caucasians

Breaking Into a Crowded Market: Otsuka’s Pioneering APRIL Inhibitor Marks New Era in Kidney Disease Treatment

Otsuka has claimed a significant victory in the increasingly competitive immunoglobulin A nephropathy (IgAN) field with FDA accelerated approval of Voyxact, the first-in-class anti-APRIL biologic therapy designed to treat this…

Continue Reading Breaking Into a Crowded Market: Otsuka’s Pioneering APRIL Inhibitor Marks New Era in Kidney Disease Treatment

FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care

As reported on FiercePharma, Johnson & Johnson has secured a significant milestone in prostate cancer treatment with the FDA’s approval of Akeega for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer…

Continue Reading FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care

When AI Sees What Radiologists Miss: How Artificial Intelligence is Reshaping Breast Cancer Detection

A groundbreaking study from Massachusetts General Hospital reveals that artificial intelligence is catching breast cancers that skilled radiologists initially overlook. As reported by Business Wire, Hologic's Genius AI Detection solution…

Continue Reading When AI Sees What Radiologists Miss: How Artificial Intelligence is Reshaping Breast Cancer Detection